Results 31 to 40 of about 489 (130)

Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy [PDF]

Journal of the American College of Cardiology
Background: Aficamten, a next-in-class cardiac myosin inhibitor, improved peak oxygen uptake (pVO2) and lowered resting and Valsalva left ventricular outflow (LVOT) gradients in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in ...
, Abraham, Theodore P., Barriales-Villa, Roberto, Cardim, Nuno, Claggett, Brian L., Coats, Caroline J., Hegde, Sheila M., Heitner, Stephen B., Jacoby, Daniel L., Jering, Karola, Kramer, Christopher M., Kupfer, Stuart, Malik, Fady I., Maron, Martin S., Masri, Ahmad, Meng, Lisa, Michels, Michelle, Nassif, Michael E., Olivotto, Iacopo, Prasad, Narayana, Roshanali, Farideh, Saberi, Sara, Solomon, Scott D., Wang, Xiaowen, Wohltman, Amy   +24 more
core   +3 more sources

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy [PDF]

, 2023
Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic New York Heart Association Classes II and III obstructive hypertrophic cardiomyopathy
Olivotto, Iacopo
core   +4 more sources

Precision medicine in complex diseases—Molecular subgrouping for improved prediction and treatment stratification

Journal of Internal Medicine, Volume 294, Issue 4, Page 378-396, October 2023., 2023
Abstract Complex diseases are caused by a combination of genetic, lifestyle, and environmental factors and comprise common noncommunicable diseases, including allergies, cardiovascular disease, and psychiatric and metabolic disorders. More than 25% of Europeans suffer from a complex disease, and together these diseases account for 70% of all deaths ...
Åsa Johansson, Ole A. Andreassen, Søren Brunak, Paul W. Franks, Harald Hedman, Ruth J. F. Loos, Benjamin Meder, Erik Melén, Craig E. Wheelock, Bo Jacobsson   +9 more
wiley   +1 more source

A pathogenic nonsense mutation (c.1522C>T) of the MYBPC3 gene is implicated with hypertrophic cardiomyopathy

ESC Heart Failure, Volume 10, Issue 4, Page 2711-2717, August 2023., 2023
Abstract Hypertrophic cardiomyopathy (HCM), a genetically and clinically heterogeneous cardiomyopathy, is commonly caused by mutations in the MYBPC3 gene or other various sarcomeric genes. HCM patients carrying sarcomeric gene mutations may experience an asymptomatic period at early stage but still possess an escalating risk of developing adverse ...
Erru Ni, Tao Wang, Xuan Zhang, Huabin Xie   +3 more
wiley   +1 more source

Pharmacokinetics of a single dose of Aficamten (CK‐274) on cardiac contractility in a A31P MYBPC3 hypertrophic cardiomyopathy cat model

Journal of Veterinary Pharmacology and Therapeutics, Volume 46, Issue 1, Page 52-61, January 2023., 2023
Abstract Hypertrophic cardiomyopathy (HCM) is the most prevalent cardiac disease in cats and lacks efficacious preclinical pharmacologic intervention, prompting investigation of novel therapies. Genetic mutations encoding sarcomeric proteins are implicated in the development of HCM and small molecule myosin inhibitors are an emerging class of ...
Ashley N. Sharpe, Maureen S. Oldach, Joanna L. Kaplan, Victor Rivas, Samantha L. Kovacs, Darren T. Hwee, Bradley P. Morgan, Fady I. Malik, Samantha P. Harris, Joshua A. Stern   +9 more
wiley   +1 more source

A New Chapter in the Management of Hypertrophic Cardiomyopathy: Cardiac Myosin Inhibitors [PDF]

, 2023
In the recent years, there has been a significant breakthrough in the treatment of hypertrophic cardiomyopathy. New precision molecules have been developed and successfully applied in clinical trials. A new class of orally available allosteric inhibitors
Olivotto Iacopo, Pálinkás Eszter Dalma, Sepp Róbert   +2 more
core   +1 more source

Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten. [PDF]

Clin Pharmacokinet
Aficamten, a small-molecule, selective cardiac myosin inhibitor, is under development for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is primarily eliminated by hepatic metabolism with renal excretion playing a minor role.
Xu D, Lutz JD, Divanji P, Li J, Benattia Y, Griffith A, Heitner SB, Kupfer S, German P.   +8 more
europepmc   +3 more sources

Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy [PDF]

New England Journal of Medicine
One of the major determinants of exercise intolerance and limiting symptoms among patients with obstructive hypertrophic cardiomyopathy (HCM) is an elevated intracardiac pressure resulting from left ventricular outflow tract obstruction. Aficamten is an oral selective cardiac myosin inhibitor that reduces left ventricular outflow tract gradients by ...
Maron, Martin S, Masri, Ahmad, Nassif, Michael E, Barriales-Villa, Roberto, Arad, Michael, Cardim, Nuno, Choudhury, Lubna, Claggett, Brian, Coats, Caroline J, Düngen, Hans-Dirk, Garcia-Pavia, Pablo, Hagège, Albert A, Januzzi, James L, Lee, Matthew M Y, Lewis, Gregory D, Ma, Chang-Sheng, Michels, Michelle, Olivotto, Iacopo, Oreziak, Artur, Owens, Anjali T, Spertus, John A, Solomon, Scott D, Tfelt-Hansen, Jacob, van Sinttruije, Marion, Veselka, Josef, Watkins, Hugh, Jacoby, Daniel L, Heitner, Stephen B, Kupfer, Stuart, Malik, Fady I, Meng, Lisa, Wohltman, Amy, Abraham, Theodore P   +32 more
openaire   +5 more sources

Is mavacamten superior to aficamten for hypertrophic cardiomyopathy? A frequentist network meta-analysis [PDF]

Exploration of Cardiology
Background: Myosin inhibitors have been shown to improve exercise capacity and symptoms, as well as reduce the left ventricular outflow tract (LVOT) gradient. This study explores the efficacy of mavacamten versus aficamten in hypertrophic cardiomyopathy (
Ayesha Aman, Bisma Akram, Arfa Akram, Momina Maham, Eisha Tariq, Aimen Hassan, Masooma Zainab Bokhari, Aleena Akram, Sania Akram, Malik Waleed Zeb Khan   +9 more
doaj   +1 more source

Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies

Frontiers in Physiology, 2022
Hypertrophic cardiomyopathy (HCM) affects more than 1 in 500 people in the general population with an extensive burden of morbidity in the form of arrhythmia, heart failure, and sudden death.
Masataka Kawana, Masataka Kawana, James A. Spudich, Kathleen M. Ruppel   +3 more
doaj   +1 more source